Non-interventional study of patients with PN NF1 starting selumetinib in Russia

Trial Identifier:	D1340R00002
Sponsor:	AstraZeneca
Start Date:	March 2023
Primary Completion Date:	March 2026
Study Completion Date:	March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia	Ekaterinburg, Russia
Russia	Kazan, Russia
Russia	Novosibirsk, Russia
Russia	Saint Petersburg, Russia
Russia, Moskva	Moscow, Moskva, Russia, 123112

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.